Welcome back to the Reflections Dyslipidemia Global Newsletter, where an international Scientific Planning Committee summarizes and provides expert commentary on the latest clinical and real-world evidence in the field of dyslipidemia. These articles are chosen based on their significance to every day clinical practice.

This newsletter focuses on the new 2024 ESC Guidelines for CCS, along with a few interesting review articles on biomarkers and risks of CV, a real-world analysis of adherence and outcomes in patients taking a single-pill combination vs. free combination of rosuvastatin and ezetimibe, a cohort study focused on combination statin/ezetimibe vs. high-intensity statin monotherapy on CV outcomes, and a clinical consensus statement from the National Lipid Association focused on dyslipidemia in women of reproductive age.

We are also pleased to share our Conference Corner, where we highlight some abstracts of interest from the recent 2024 ESC Congress which took place in London, England.

As with the previous newsletters, we invite you to interact through links to short video commentaries from our SPC, links to videos or podcasts, along with hyperlinks to full articles for in-depth study and reflection.

Prof. Farnier (Chair)

Key articles in Newsletter #8: